BHC Bausch Health Aggregate Debt Obligations

Despite the implementation of automated filling and molding lines, Bausch Health Companies (BHC) relies on diversification within aesthetics and ophthalmology. The total liabilities metric reflects the dynamics of borrowed capital, where 0.00 serves as the final level marker. Complex production cycles and patent protection ensure business resilience, creating high barriers to entry for new market players.

Company Aggregate Debts: Valeant Pharmaceuticals (BHC) for 07/04/2022 - 10/28/2026

Analytical breakdowns and data insights for company Bausch Health (BHC)

- price and consensus price forecast:

Stock Price Bausch Health Corp|BHC - Price Target Chart

- market capitalization data:

Market Value Valeant Pharmaceuticals|BHC - Total Company Value

- book capitalization data:

Accounting Value per Share Bausch Health|BHC - Book Capitalization|Market Capitalization to Book Value Ratio bauschhealth.com|BHC - Cumulative Company Assets

- debt and liquidity data:

All Debt to Shareholders' Equity Ratio Bausch Health Companies|BHC - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Bausch Health Companies Inc.|BHC - Company Debts|Debts to Book Value Valeant Pharmaceuticals|BHC - Company Long-Term Debt|Company Short-Term Debt Bausch Health

Fundamental company valuation:Bausch Health Corp BHC

Signature product of Bausch Health Companies Inc.

Bausch Health Companies (BHC) utilizes stable cash flows from its ophthalmology and gastroenterology segments to systematically service its debt obligations. By analyzing the debt trajectory, investors assess the total volume of external loans, where a decrease in this metric indicates growing financial autonomy and issuer reliability, while excessive leverage may constrain business growth potential.

Competitors of Bausch Health Companies